Lifeward (NASDAQ:LFWD), a global leader in innovative medical technology for individuals with physical limitations, today announced the national launch of its ReWalk 7 Personal Exoskeleton in the United States.
This marks the release of the next generation of the company's groundbreaking personal exoskeleton technology.
The ReWalk 7 introduces several new and enhanced features designed to provide a more functional and personalized walking experience for individuals with spinal cord injuries (SCI).
Key advancements include cloud connectivity and customizable walking speeds.
Larry Jasinski, CEO of Lifeward, expressed his enthusiasm for the launch, stating, "The ReWalk 7 was developed over several years, integrating advanced technological innovations with feedback from clinicians and patients to build upon the ReWalk’s world-class reputation for industry leadership. The result is a device that is optimized for real-world use, with an unmatched user experience and freedom of movement.”
Lifeward emphasized the collaborative development process, noting that they worked closely with over two dozen end users and physical therapists during the FDA clearance process to gather critical feedback on the device's impact in both rehabilitation and everyday settings.
The ReWalk 7 is now available for purchase in the U.S. for both personal use by individuals with spinal cord injuries and for use in clinical settings.